# Aaron N. Hata
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/aaron-n-hata/
## Facts
| Field | Value |
| --- | --- |
| Citations | 15,163 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 55 |
| i10-index | 98 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5087906702 |
| ORCID iD | 0000-0002-6127-318X |
| Works | 522 |
## Researcher papers
- [EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis](https://scholariq.org/papers/i-egfr-i-mutations-and-i-alk-i-rearrangements-are-associated-with-low-response/)
- [Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition](https://scholariq.org/papers/tumor-cells-can-follow-distinct-evolutionary-paths-to-become-resistant-to/)
- [Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation](https://scholariq.org/papers/pharmacology-and-signaling-of-prostaglandin-receptors-multiple-roles-in/)
- [A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors](https://scholariq.org/papers/a-single-cell-and-single-nucleus-rna-seq-toolbox-for-fresh-and-frozen-human/)
- [The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics](https://scholariq.org/papers/the-bcl2-family-key-mediators-of-the-apoptotic-response-to-targeted-anticancer/)
- [The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution](https://scholariq.org/papers/the-human-tumor-atlas-network-charting-tumor-transitions-across-space-and-time/)
- [Cycling cancer persister cells arise from lineages with distinct programs](https://scholariq.org/papers/cycling-cancer-persister-cells-arise-from-lineages-with-distinct-programs/)
- [Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation](https://scholariq.org/papers/clinical-acquired-resistance-to-krasg12c-inhibition-through-a-novel-kras-switch/)
- [Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor](https://scholariq.org/papers/heterogeneity-underlies-the-emergence-of-i-egfr-i-t790-wild-type-clones/)
- [Landscape of Acquired Resistance to Osimertinib in EGFR -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion](https://scholariq.org/papers/landscape-of-acquired-resistance-to-osimertinib-in-i-egfr-i-mutant-nsclc-and/)
- [Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling](https://scholariq.org/papers/detecting-small-cell-transformation-in-patients-with-advanced-i-egfr-i-mutant/)
- [Complete evaluation of resistance mechanisms to first-line osimertinib requires tissue biopsy.](https://scholariq.org/papers/complete-evaluation-of-resistance-mechanisms-to-first-line-osimertinib-requires/)
## Researcher topics
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer therapeutics and mechanisms](https://scholariq.org/topics/cancer-therapeutics-and-mechanisms/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
## Researcher university
- [Harvard University](https://scholariq.org/institutions/harvard-university/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.